More Evidence That Contrast-Induced Nephropathy Is Not Clinically Important

A large meta-analysis of observational studies finds no evidence of risk.

A recent propensity-match-controlled observational study suggested that modern radiographic contrast does not increase the risk for nephropathy (NEJM JW Emerg Med Mar 2017 and Ann Emerg Med 2017; 69:577). Now, investigators report the results of a large meta-analysis of observational studies that compared renal outcomes in patients undergoing computed tomography (CT) who received radiographic contrast and those who did not receive contrast.

Twenty-eight studies involving more than 100,000 patients were included in the meta-analysis. Most of the studies (82%) included patients with baseline renal insufficiency. The analysis showed that contrast-enhanced CT, compared with CT without contrast, was not significantly associated with acute kidney …

Reviewing Author

Daniel J. Pallin, MD, MPH

Disclosures

Consultant/Advisory BoardPortola Pharmaceuticals, Inc.

Speaker’s BureauPeerView Institute for Medical Education

Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals

Daniel J. Pallin, MD, MPH

Disclosures

Consultant/Advisory BoardPortola Pharmaceuticals, Inc.

Speaker’s BureauPeerView Institute for Medical Education

More Evidence That Contrast-Induced Nephropathy Is Not Clinically Important

Topics

Reviewing Author